Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

were similar for all treatment groups -- 91 percent reported at least one adverse event in the placebo/desvenlafaxine succinate group; 86 percent in the venlafaxine ER/desvenlafaxine succinate group; and 86 percent in the desvenlafaxine succinate/desvenlafaxine succinate group. The incidence of nausea was highest for the placebo/desvenlafaxine succinate group during the first week of treatment and decreased to rates similar to the venlafaxine ER/desvenlafaxine succinate group (p= 0.03) and the desvenlafaxine succinate/desvenlafaxine succinate group at Day 8 and beyond. Additionally, discontinuation rates due to adverse events were highest in the placebo/desvenlafaxine succinate group and lowest in the desvenlafaxine succinate/desvenlafaxine succinate group (placebo/desvenlafaxine succinate: 23 percent; venlafaxine ER/desvenlafaxine succinate: 16 percent; desvenlafaxine succinate/desvenlafaxine succinate: 11 percent).

Poster NR299: Feiger AD, et al. A Placebo-Controlled Efficacy and Safety Study of a Flexible Dose of Desvenlafaxine Succinate in Outpatients with Major Depressive Disorder

According to the results of a Phase 3, multicenter, double-blind, placebo- controlled, parallel-group, flexible-dose study, there was no significant difference between patients receiving placebo and those receiving desvenlafaxine succinate based on the primary endpoint of change from baseline in the HAM-D17 total score at the final evaluation of Week 8, using analysis of co-variance with last-observation-carried-forward (LOCF) analyses. However, based on observed-cases analysis of the primary endpoint, there was a significant difference at Week 8 between patients who took desvenlafaxine succinate vs. patients receiving placebo. Based on LOCF and observed-case analysis of various secondary endpoints, desvenlafaxine succinate was significantly better than placebo.

Patients in this study were randomized to receive desvenlafaxine succinate 200 to 400 mg/day (n=117) o
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated ... of non-constipating irritable bowel syndrome (IBS). Top-line results ... times daily produced a statistically significant improvement in global ...
... (OTC Bulletin Board: CONX), a worldwide developer and marketer of ... first fiscal quarter ended September 30, 2009, compared with $2,001,896 ... 2.2%. , The first quarter of fiscal 2010 produced operating ... for the first quarter of fiscal 2009. The net loss ...
Cached Medicine Technology:Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 5Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3
(Date:4/18/2014)... What,s one of your worst memories? How did it ... felt during a negative personal experience, such as how ... lead to emotional distress, especially when you can,t stop ... creep up, thinking about the context of the memories, ... and effective way to alleviate the negative effects of ...
(Date:4/18/2014)... have made a brain-related discovery that could revolutionize ... This discovery opens up the possibility that environmental ... specific brain activity that the researchers have identified ... Journal of Neuroscience has just published a ... associate professor of psychology and his doctoral student ...
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... death risk, study finds , WEDNESDAY, Aug. 12 (HealthDay ... early non-invasive ventilation after a breathing tube has been ... die, a Spanish study has found. , The study ... had high levels of carbon dioxide in their blood, ...
... , GUANGZHOU, China, Aug. 13 ... Medicine" or "the Company"), a developer,and a leading distributor ... (TCM), nutritional and dietary supplements, and,medical devices and medical ... Second Quarter 2009 Highlights:, ...
... From cranky bosses to incompetent coworkers, traffic jams, inconsiderate drivers, ... way through the typical work day in big cities are enough ... , Tanna Marshall, a holistic health consultant and ... natural health practitioner, offers a collection of tips and advice to ...
... , , THOUSAND OAKS, ... today will summarize data from the submitted Biologic License Applications (BLAs) ... the prevention and treatment of bone loss in breast and prostate ... Food and Drug Administration,s (FDA) Advisory Committee for Reproductive Health Drugs ...
... , NEW YORK, Aug. 13 Terraboost -- ... announced a new program today to provide complimentary touch-free hand ... mitigate risk related to H1N1 swine flu and other disease-causing ... ) , , With the ...
... , ... In September of 2008 SpeechNutrients introduced the ... nutritional support for children with apraxia and speech challenges. A ... Health and Medicine reported that 181 children with verbal apraxia taking ...
Cached Medicine News:Health News:Ventilation After Breathing Tube Removal May Alter Outcomes 2Health News:China Medicine Announces Second Quarter 2009 Results 2Health News:China Medicine Announces Second Quarter 2009 Results 3Health News:China Medicine Announces Second Quarter 2009 Results 4Health News:China Medicine Announces Second Quarter 2009 Results 5Health News:China Medicine Announces Second Quarter 2009 Results 6Health News:China Medicine Announces Second Quarter 2009 Results 7Health News:China Medicine Announces Second Quarter 2009 Results 8Health News:China Medicine Announces Second Quarter 2009 Results 9Health News:China Medicine Announces Second Quarter 2009 Results 10Health News:China Medicine Announces Second Quarter 2009 Results 11Health News:China Medicine Announces Second Quarter 2009 Results 12Health News:China Medicine Announces Second Quarter 2009 Results 13Health News:China Medicine Announces Second Quarter 2009 Results 14Health News:'Living Peacefully in a Big City': Natural Health Practitioner Offers Advice on Maintaining Sanity, Health and Happiness 2Health News:'Living Peacefully in a Big City': Natural Health Practitioner Offers Advice on Maintaining Sanity, Health and Happiness 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 2Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 4Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 5Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 6Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 7Health News:Terraboost Unveils Free H1N1 Risk Mitigation Product 2Health News:Terraboost Unveils Free H1N1 Risk Mitigation Product 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 2Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: